Maven Securities’s Trillium Therapeutics Inc. TRIL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-95,000
Closed -$1.02M 1500
2021
Q1
$1.02M Buy
+95,000
New +$1.17M 0.05% 402

Other funds holding TRIL

Maven Securities's TRIL Position: Q4 2021 in Review

Maven Securities sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 20,000 shares — an estimated $351K sold.

Maven Securities first reported a position in TRIL in Q4 2020 and held it in 3 quarters. The position peaked at $2.98M in Q1 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

  • Maven Securities reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
  • Maven Securities sold 20,000 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $351K.
  • Maven Securities first reported a position in Trillium Therapeutics Inc. in Q4 2020 and held it in 3 quarters.
  • Maven Securities's Trillium Therapeutics Inc. position peaked at $2.98M in Q1 2021.
  • 2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Maven Securities's 13F filing for Q4 2021, filed 14 Feb 2022.